Paper Details

  1. Home
  2. Paper Details

A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by Sex.

Author: , ArronJoseph R, BraddingPeter, BrightlingChris E, BusbyJohn, ChaudhuriRekha, ChoyDavid F, CowanDouglas, DjukanovicRatko, EastwoodMatthew C, FowlerStephen J, HanrattyCatherine E, HardmanTimothy C, HarrisonTimothy, HeaneyLiam G, HolwegCecile T J, HowarthPeter, JacksonDavid J, LordanJames, MansurAdel H, MatthewsJohn G, Menzies-GowAndrew, PavordIan D, RobinsonDouglas S, WalkerSamantha, WoodcockAshley

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This post hoc analysis examined the effects of sex on outcomes in a clinical trial comparing biomarker-defined corticosteroid (CS) treatment with standard care for severe asthma. Females achieved a greater benefit from biomarker-directed CS optimization than males, suggesting that sex-specific treatment considerations may be necessary in severe asthma.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Approximately 5% to 10% of patients with asthma have severe disease, with a consistent preponderance in females. Current asthma guidelines recommend stepwise treatment to achieve symptom control with no differential treatment considerations for either sex. OBJECTIVE: To examine whether ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jaip.2022.12.019

データ提供：米国国立医学図書館（NLM）

Severe Asthma Treatment: A Tailored Approach for Women?

The world of severe asthma treatment is a vast desert, with many different approaches to navigating its complexities. This research is a fascinating journey, using a composite T2-biomarker score to help guide corticosteroid (CS) therapy. The researchers used a randomized controlled clinical trial to explore whether a biomarker-defined treatment algorithm could be a better guide for severe asthma patients compared to the standard care. They discovered a striking difference: the biomarker algorithm led to a greater proportion of females being on a lower CS dose compared to standard care, which was not seen in males. This suggests a need for a more tailored approach to treatment, especially for women with severe asthma.

Biomarker-Directed Treatment: A Promising Path for Women

These findings present a promising outlook for women with severe asthma. The use of T2-biomarkers as a tool to guide CS treatment could lead to better control and a lower risk of exacerbations. The study indicates that women may benefit from this more personalized approach to their care.

Navigating the Desert of Asthma: A Personalized Oasis for Women

These results emphasize the need for individualised care in the treatment of severe asthma. Just as a desert traveler needs to choose the right path for their journey, so too do individuals with severe asthma. The study suggests that, for women, biomarker-directed treatment could be the oasis they need for better control and a more comfortable journey.

Dr.Camel's Conclusion

This study suggests that women with severe asthma may benefit from a tailored approach to treatment that utilizes biomarker-directed corticosteroid optimization. It's a step towards a more personalized approach to asthma care, a journey that requires considering the unique needs of each patient. Just like the desert provides diverse paths and oases for different travelers, we must strive to offer personalized solutions for those navigating the challenges of severe asthma.

Date :
  1. Date Completed 2023-04-11
  2. Date Revised 2023-05-13
Further Info :

Pubmed ID

36621603

DOI: Digital Object Identifier

10.1016/j.jaip.2022.12.019

Related Literature

Article Analysis
・Effective treatment of asthma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.